The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the healthcare community. This novel dual GIP and GLP-1 agonist medication suggests to deliver notable improvements in body reduction compared to current therapies. Early research studies have indicated substantial decreases in body fat percentage,